C12N 2760/18721
Viruses as such
Official title: Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N2760/18721 (Viruses as such) appears on 17 US grants and 22 published applications in this corpus.
Search patents in C12N- Granted patents
- 17
- Published applications
- 22
- Assignees
- 12
- Inventors
- 33
- Latest grant
- 2 Dec 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 1 |
| 2003 | 1 | 1 |
| 2004 | 0 | 1 |
| 2005 | 1 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 2 |
| 2015 | 0 | 1 |
| 2016 | 1 | 0 |
| 2017 | 2 | 3 |
| 2018 | 0 | 1 |
| 2019 | 1 | 2 |
| 2020 | 2 | 2 |
| 2021 | 1 | 1 |
| 2022 | 1 | 3 |
| 2023 | 2 | 0 |
| 2024 | 1 | 3 |
| 2025 | 2 | 0 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- F-genotype mumps virus attenuated strain and construction method therefor and application thereof2 Dec 2025US 12,486,497 B2Beijing Cell-Fusion Biotechnology Co., Ltd.
- Oncolytic viruses for sensitizing tumor cells to killing by natural killer cells27 May 2025US 12,312,393 B2University of Central Florida Research Foundation, Inc.
- Mumps virus as a potential oncolytic agent19 Mar 2024US 11,932,879 B2Mayo Foundation for Medical Education and Research
- Oncolytic viruses for sensitizing tumor cells to killing by natural killer cells27 Jun 2023US 11,684,637 B2University of Central Florida Research Foundation, Inc.
- Parainfluenza virus 5 based vaccines3 Jan 2023US 11,542,527 B2University of Georgia Research Foundation, Inc.
- Method of producing negative-strand rna virus vector and produced negative-strand rna virus vector27 Aug 2026US 2026/0250709 A1Repli-Tech Co., Ltd.
- Attenuated mumps vaccine and uses thereof26 Sep 2024US 2024/0316180 A1Korea National Institute of Health
- Method of producing negative-strand rna virus vector and produced negative-strand rna virus vector19 Sep 2024US 2024/0309335 A1Repli-Tech Co., Ltd.
- Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells4 Jan 2024US 2024/0000842 A1University of Central Florida Research Foundation, Inc.
- F-genotype mumps virus attenuated strain and construction method therefor and application thereof8 Dec 2022US 2022/0389391 A1Beijing Cell-Fusion Biotechnology Co., Ltd.
Most cited
By later US patents
- Porcine parainfluenza virus type 233US 5,910,310 ABayer Aktiengesellschaft · 1999
- Vaccine against mumps containing a Jeryl-Lynn virus strain2US 6,024,962 ASmithKline Beecham Biologicals s.a. · 2000
- Mumps virus as a potential oncolytic agent1US 10,577,591 B2Mayo Foundation for Medical Education and Research · 2020
- Parainfluenza virus 5 based vaccines1US 10,752,916 B2University of Georgia Research Foundation, Inc. · 2020
- Mumps virus as a potential oncolytic agent1US 11,401,511 B2Mayo Foundation for Medical Education and Research · 2022